Test description
PIK3CA, AKT1 and PTEN pathogenic variants are associated with potentially targeted therapies. ESR1 mutations are linked to endocrine therapy resistance and can guide other treatments. Fusions may be targetable with kinase inhibitors. NTRK fusions are diagnostic of secretory carcinoma of the breast.
Test information
Test name
Breast cancer solid tumour panel
Clinical indication
Testing of breast cancer tissue to determine suitable treatment.
Gene(s)
DNA: AKT1, PIK3CA, PTEN, ESR1
CNV: ERBB2 amp
RNA: RET fusion, NTRK fusion
Method
NGS Oncomine Precision Assay
Turn around time
5 business days from receipt of sample
Medicare eligibility
Price
DNA only: $425
DNA & RNA: $799
Test request form
Somatic Genetic Testing Request Form
Sample type
FFPE Tumour Tissue
Collection type
Special instructions
6 x 5µm slides plus 1 x H&E stained slide required